Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 21, 2020 12:45 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Highlights Stage IV M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Near-resolution of tumor burden, including extensive visceral hepatic diseaseExpanded data set of trial subject provided KNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT)...
September 17, 2020 07:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

36% ORR and 64% DCR (RECIST 1.1)PV-10-induced, tumor-specific restoration of T cell functionData compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN,...
September 17, 2020 06:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient...
September 09, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance

KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...
August 13, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment

University of Calgary researchers have successfully demonstrated initial, in vivo proof-of-concept, oral rose bengal disodium treatment for blood cancerResearchers will now investigate oral treatment...
July 22, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptance of Two PV-10® Melanoma Cancer Abstracts at European Society for Medical Oncology (ESMO) Virtual Congress 2020

KNOXVILLE, TN, July 22, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that data from an ongoing clinical trial of investigational autolytic cancer immunotherapy PV-10...
July 16, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Change to Board of Directors

KNOXVILLE, TN, July 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the addition of Webster Bailey to the Company's Board of Directors (the “Board”), effective as...
June 22, 2020 07:30 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Discovery of Unique PV-10®-Induced STING Pathway Mechanism for Presentation at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II

PV-10 treatment leads to STING dimerizationResearchers identify potential association of heat shock proteins with STING in PV-10-treated models KNOXVILLE, TN, June 22, 2020 (GLOBE NEWSWIRE) --...
June 09, 2020 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Global Patent Portfolio to India for Cancer Combination Therapy

2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing processProvectus further expands cancer combination therapy IP protection by filing new USPTO patent...
June 01, 2020 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Treatment refractory, immunologically cold, hepatic tumor type37% reduction and 83% stabilization of treated disease (2D-EASL)Overall survival of 11 months for checkpoint inhibition-naïve patients;...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right